Mereo BioPharma Group plc

MREO

Nasdaq; healthcare; SIC 2834, Pharmaceutical Preparations; CIK 0001719714

None

No letter

5 of 14 inputs computable; 7 are required, with a score in every sleeve

Scoreboard	
Reliability	0.83 AUC filers with $12.5M to $120M assets; 95% interval 0.79 to 0.86; 201 events, 2020 to 2025
Peer failure rate	1.07% a year Item 1.03 bankruptcies, same asset band, 2012 to 2025
Size band	$12.5M to $120M assets total assets $45.9M
Standard universe	outside revenue above $1M and assets above $10M
Warnings	thin data not computable: distress, fortress balance sheet
Inputs computable	5 of 14
Graded from	filings received through Mar 19, 2026 230 days before the rescan; latest periodic filing 10-Q received Aug 11, 2026
Last close	$0.30 2026-11-03; market equity $235.9M; no price enters the letter

Share price, twelve months to the rescan



Split-adjusted close. Each lollipop is a rescan and carries the letter held then.

Letter at every rescan, 2012 to 2026



Sector percentile at each rescan, stronger toward the top; facts filed by each date only.

Business, in the company's words

opening of Item 1 of the 10-K received Mar 19, 2026

-Core Rare Disease Product Candidates-Setrusumab (BPS-804/UX143) for the Treatment of Osteogenesis Imperfecta-Top-line Data from Setrusumab Phase 3 Orbit and Cosmic Studies." We do not know whether our planned clinical trials will begin on time or be completed on schedule, if at all.

The fourteen inputs

lower percentile is stronger; sleeves and inputs within a sleeve carry equal weight

Input	Value	Peer median	Percentile, 0 to 100	Pct	Peers	Period end
Profitability, sleeve percentile 24.4						
Gross profitability	not computable	32.4%				
one or more required annual facts are missing						
Return on invested capital	not computable	9.3%				
one or more required annual facts are missing						
Accruals ratio	(17.8%)	(6.6%)		24.4	803	2025-12-31

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

Gross margin stability, five years	not computable	2.8 pts				
five annual gross margins are required; found 0						
Solvency, sleeve percentile 63.3						
Twelve-month failure probability	not computable	0.08%				
liabilities and a nearby cover-page share count are required at 2025-12-31						
Altman Z double-prime	(27.03)	(0.35)		78.6	747	2025-12-31
Net debt to EBITDA	not computable	1.82x				
one or more required annual facts are missing						
Interest coverage	(157.28x)	(4.51x)		96.1	78	2025-12-31
Current ratio	10.46x	2.92x		15.2	828	2025-12-31
Growth and financing, sleeve percentile 17.4						
Revenue growth, three-year compound	not computable	10.1%				
four annual observations are required; found 3						
Free cash flow growth, three-year compound	not computable	10.9%				
four consecutive annual FCF observations are required; found 2						
Reinvestment rate	not computable	37.1%				
NOPAT must exceed $100,000						
Asset growth, three years	not computable	2.2%				
four annual observations are required; found 3						
Net share issuance, one year	0.4%	2.5%		17.4	632	2026-03-18

Warnings

1 of 7 checks triggered; none of them enters the letter

Check	Measured
Thin data	5 of 14 grade factors are computable; minimum is 7

What the price implies

at the 2026-11-03 close; none of these enters the grade

Measure	Value	Peer median	Percentile
Twelve-month price change, skipping the latest month	(78.8%)	(2.2%)	6
Distance from 52-week high	(87.4%)	(29.8%)	5
EBIT to enterprise value	not computable	(1.5%)	
Free cash flow yield	(13.3%)	(0.9%)	28
Book value to price	0.12	0.28	30
Sales to price	0.00	0.30	4
Composite equity issuance, five years	not computable	20.5%	
Relative strength against the sector, log excess return	(1.72)	(0.19)	6

Diagnostics

shown on every report; none enters the grade

Measure	Value
Piotroski F-score None of 9, period end 2025-12-31	
Return on assets above zero	fail
Operating cash flow above zero	fail
Return on assets improved	pass
Operating cash flow exceeds net income	pass
Long-term leverage fell	fail
Current ratio improved	pass
No new shares issued	fail
Gross margin improved	fail
Asset turnover improved	pass

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

Cash, filings, liquidity	
Cash and equivalents	$30.1M
Operating cash flow, four quarters	-$25.3M
Months of runway	14.3
Days since last periodic filing	85 (10-Q received Aug 11, 2026)
Median daily dollar volume, 63 sessions	$350,832

Sources

every fact behind the inputs; each row links to its filing index on sec.gov

#	Concept	XBRL tag	Value	Period end	Received	Form	Accession
1	net income	us-gaap:NetIncomeLoss	-$41.9M	2025-12-31	2026-03-19	10-K	26-115226
2	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	-$31.0M	2025-12-31	2026-03-19	10-K	26-115226
3	assets	us-gaap:Assets	$45.9M	2025-12-31	2026-03-19	10-K	26-115226
4	assets	us-gaap:Assets	$76.4M	2024-12-31	2026-03-19	10-K	26-115226
5	current assets	us-gaap:AssetsCurrent	$45.0M	2025-12-31	2026-03-19	10-K	26-115226
6	current liabilities	us-gaap:LiabilitiesCurrent	$4.3M	2025-12-31	2026-03-19	10-K	26-115226
7	retained earnings	us-gaap:RetainedEarningsAccumulatedDeficit	-$501.0M	2025-12-31	2026-03-19	10-K	26-115226
8	operating income	us-gaap:OperatingIncomeLoss	-$40.1M	2025-12-31	2026-03-19	10-K	26-115226
9	book equity	us-gaap:StockholdersEquity	$40.9M	2025-12-31	2026-03-19	10-K	26-115226
10	liabilities	us-gaap:Liabilities	$5.0M	2025-12-31	2026-03-19	10-K	26-115226
11	interest expense	us-gaap:InterestExpense	$255,000	2025-12-31	2026-03-19	10-K	26-115226
12	revenue	us-gaap:Revenues	$500,000	2025-12-31	2026-03-19	10-K	26-115226
13	revenue	us-gaap:Revenues	$0	2024-12-31	2026-03-19	10-K	26-115226
14	revenue	us-gaap:Revenues	$10.0M	2023-12-31	2025-03-26	10-K	25-044787
15	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	$20,000	2025-12-31	2026-03-19	10-K	26-115226
16	depreciation amortization	us-gaap:Depreciation	$157,000	2025-12-31	2026-03-19	10-K	26-115226
17	pretax income	us-gaap:IncomeLossFromContinuingOperationsBeforeInc...	-$41.9M	2025-12-31	2026-03-19	10-K	26-115226
18	income tax	us-gaap:IncomeTaxExpenseBenefit	$0	2025-12-31	2026-03-19	10-K	26-115226
19	current assets	us-gaap:AssetsCurrent	$74.8M	2024-12-31	2026-03-19	10-K	26-115226
20	current liabilities	us-gaap:LiabilitiesCurrent	$13.8M	2024-12-31	2026-03-19	10-K	26-115226
21	assets	us-gaap:Assets	$66.5M	2023-12-31	2025-03-26	10-K	25-044787
22	shares outstanding	dei:EntityCommonStockSharesOutstanding	798,078,829	2026-03-18	2026-03-19	10-K	26-115226
23	shares outstanding	dei:EntityCommonStockSharesOutstanding	795,001,444	2025-03-25	2025-03-26	10-K	25-044787

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.